Akebia Therapeutic's Vafseo® (vadadustat) Granted Additional Patent
Akebia Therapeutics announced that a new patent has been granted for Vafseo® (vadadustat), strengthening its vadadustat intellectual property portfolio. The patent term extends until 2043.
Why it matters — AKBA watchers may note the patent grant as an addition to the company's intellectual property protection for Vafseo.